Oncolytics Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Oncolytics Biotech
ONCY Stock  USD 0.89  0.05  5.95%   
Oncolytics Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oncolytics Biotech's valuation are provided below:
Market Capitalization
95.3 M
Earnings Share
(0.29)
We have found one hundred twenty available trending fundamental ratios for Oncolytics Biotech, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Oncolytics Biotech recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 109.8 M in 2026. Enterprise Value is likely to drop to about 93.5 M in 2026

Oncolytics Biotech Total Revenue

4.85 Million

Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 87.2 K, Interest Expense of 637.6 K or Selling General Administrative of 16.1 M, as well as many indicators such as Price To Sales Ratio of 66.83, Dividend Yield of 0.0 or PTB Ratio of 20.28. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.
  
Build AI portfolio with Oncolytics Stock
Check out the analysis of Oncolytics Biotech Correlation against competitors.
For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Oncolytics Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets30.1 M23.2 M25.6 M
Slightly volatile
Total Current Liabilities4.1 M7.7 M4.9 M
Pretty Stable
Property Plant And Equipment Net1.6 M1.5 M671.8 K
Slightly volatile
Accounts Payable1.2 M1.3 M2.6 M
Slightly volatile
Cash19.3 M18.3 M20.3 M
Pretty Stable
Non Current Assets Total1.8 M1.2 M873.1 K
Pretty Stable
Cash And Short Term Investments26.2 M18.3 M22.6 M
Pretty Stable
Net Receivables74.3 K78.2 K555.9 K
Very volatile
Common Stock Shares Outstanding92.4 M88 M38.1 M
Slightly volatile
Liabilities And Stockholders Equity30.1 M23.2 M25.6 M
Slightly volatile
Other Current Assets3.5 M3.3 M1.7 M
Slightly volatile
Other Stockholder Equity42.2 M40.1 M31 M
Slightly volatile
Total Liabilities17.2 M16.3 M9.3 M
Slightly volatile
Total Current Assets27.7 M21.7 M24.7 M
Slightly volatile
Common Stock529.1 M503.9 M311.9 M
Slightly volatile
Property Plant Equipment377.8 K749.8 K495.6 K
Slightly volatile
Capital Surpluse29 M37.9 M24.3 M
Slightly volatile
Net Working Capital24.9 M14 M18.1 M
Slightly volatile
Capital Stock411.3 M503.9 M342 M
Slightly volatile

Oncolytics Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization87.2 K91.8 K181.6 K
Slightly volatile
Selling General Administrative16.1 M15.3 M8.2 M
Slightly volatile
Other Operating Expenses42.2 M40.2 M23.2 M
Slightly volatile
Research Development12.5 M24.9 M14.1 M
Very volatile
Total Operating Expenses42.2 M40.2 M23.1 M
Slightly volatile
Net Interest Income1.4 M1.4 M444.4 K
Slightly volatile
Interest Income1.4 M1.4 M444.4 K
Slightly volatile
Reconciled Depreciation382.4 K487.6 K252.1 K
Slightly volatile
Selling And Marketing Expenses18.9 M18 M5.3 M
Slightly volatile

Oncolytics Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow42.2 M40.1 M24 M
Slightly volatile
Depreciation301.8 K381.6 K253.7 K
Slightly volatile
Capital Expenditures210.4 K215.1 K130 K
Very volatile
Total Cash From Financing Activities7.2 M7.6 M17.1 M
Very volatile
End Period Cash Flow19.3 M18.3 M20.3 M
Pretty Stable
Stock Based Compensation3.3 M3.1 M1.7 M
Slightly volatile
Issuance Of Capital Stock5.9 M6.2 M16.2 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio66.8370.3482.4897
Slightly volatile
Days Sales Outstanding3.73.8912.7717
Slightly volatile
Average Payables1.7 M1.1 M2.8 M
Slightly volatile
Stock Based Compensation To Revenue0.120.140.1482
Slightly volatile
Capex To Depreciation0.620.651.4385
Slightly volatile
EV To Sales62.4865.7675.3695
Slightly volatile
Inventory Turnover127142155
Slightly volatile
Payables Turnover0.180.250.2573
Slightly volatile
Sales General And Administrative To Revenue0.120.140.1482
Slightly volatile
Research And Ddevelopement To Revenue13.117.447.2395
Pretty Stable
Capex To Revenue0.02850.030.0341
Slightly volatile
Cash Per Share0.230.241.2473
Slightly volatile
Days Payables Outstanding1.4 K1.5 K3.6 K
Pretty Stable
Income Quality0.710.770.8851
Slightly volatile
Intangibles To Total Assets0.01410.01490.0334
Slightly volatile
Net Debt To EBITDA0.470.491.383
Slightly volatile
Current Ratio3.083.258.8877
Slightly volatile
Receivables Turnover10297.08101
Slightly volatile
Capex Per Share0.00340.00360.0082
Slightly volatile
Average Receivables186.4 K177.5 K154.5 K
Slightly volatile
Revenue Per Share0.570.550.5752
Slightly volatile
Interest Debt Per Share0.01520.0160.017
Slightly volatile
Debt To Assets0.04980.04740.0264
Slightly volatile
Days Of Payables Outstanding1.4 K1.5 K3.6 K
Pretty Stable
Ebt Per Ebit0.80.810.9689
Pretty Stable
Long Term Debt To Capitalization0.00890.00560.0061
Slightly volatile
Total Debt To Capitalization0.0880.140.7
Slightly volatile
Quick Ratio3.083.258.8877
Slightly volatile
Net Income Per E B T0.810.91.0066
Pretty Stable
Cash Ratio2.62.747.9278
Slightly volatile
Days Of Sales Outstanding3.73.8912.7717
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.161.0242
Slightly volatile
Fixed Asset Turnover11.210.6711.3588
Slightly volatile
Debt Ratio0.04980.04740.0264
Slightly volatile
Price Sales Ratio66.8370.3482.4897
Slightly volatile
Asset Turnover0.210.20.2059
Slightly volatile

Oncolytics Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap109.8 M115.6 M368.9 M
Slightly volatile
Enterprise Value93.5 M98.5 M349.1 M
Slightly volatile

Oncolytics Fundamental Market Drivers

Oncolytics Upcoming Events

1st of March 2024
Upcoming Quarterly Report
View
3rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Oncolytics Biotech Financial Statements

Oncolytics Biotech investors use historical fundamental indicators, such as Oncolytics Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncolytics Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-973.8 K-925.1 K
Cost Of Revenue268.7 K255.3 K
Stock Based Compensation To Revenue 0.14  0.12 
Sales General And Administrative To Revenue 0.14  0.12 
Research And Ddevelopement To Revenue 7.44  13.11 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.55  0.57 
Ebit Per Revenue(6.81)(7.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY